Grameva (539120)

Score breakdown: P/E: 0/3 · ROCE: 0/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Revenue momentum: 128.55% sales growth shows strong recent demand.
• Positive book value of ₹17.95 per share provides some asset support.
• Trading near its 52-week high of ₹70.00, indicating market interest.
• ROCE of 9.42% is better than ROE, suggesting some operating efficiency at the capital level.

Concerns

• Extremely rich valuation: P/E of 60.48 and P/B of 3.80 against ROE of only 6.30%.
• Profitability is deteriorating: profit growth is -43.75% and latest quarter net profit is ₹0 Cr.
• No dividend yield, so shareholders get no cash return while waiting.
• Piotroski F-score of 4/9 and missing promoter/debt data make financial health and governance hard to assess.

AI Analysis

As a value investor, I look for businesses that earn high returns on tangible capital and have an enduring moat. Grameva does neither. This is a ₹34 crore jute company trading at ₹68.22, or 3.80 times its ₹17.95 book value, yet it earns only 6.30% on equity and 9.42% on capital. In Graham's language, the market is paying a rich price for modest, cyclical earnings. Revenue jumped 128.55%, which sounds exciting, but profit fell 43.75%. The latest quarter tells the real story: ₹13 crore of sales and zero net profit. This is a business that cannot convert its top line into shareholder earnings. High sales in jute often reflects commodity price swings, not a durable competitive advantage. With a P/E of 60.48, the purchase price already assumes a great future. I see no margin of safety. The Piotroski F-score of 4/9 supports my caution; the fundamental health is mediocre. There is no dividend to compensate while waiting. A PEG of 0.47 is a trap because the denominator—earnings growth—is negative. I cannot value a company when promoter holding and debt/equity are unknown; that is an information blackout. Jute is inherently cyclical, and small Indian jute mills face raw material and labour cost pressures. Without pricing power or high margins, a 128% sales surge can quickly reverse. My rule: buy wonderful businesses at fair prices. Grameva is not wonderful, and at 60 times earnings it is far from fair. I would keep this on my watchlist and wait for either a much lower price, a clear improvement in profitability, or evidence of a structural edge. Today, the risk-reward is unfavorable.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer